小柯机器人

中山大学肿瘤中心徐瑞华和王峰研究组合作对晚期食管鳞状细胞癌(ESCC)化疗加PD-1阻断进行了免疫原性和致癌性特征分类。2023年4月13日出版的《癌细胞》杂志发表了这一最新研究成果。

他们对JUPITER-06研究中486例患者的肿瘤样本进行了全外显子组测序，并开发了一种拷贝数改变校正的肿瘤突变负担，更精确地描述免疫原性并预测化疗+抗PD-1疗效。他们确定了其他几个有利的免疫原性特征(例如，HLA-I/II多样性)和与化疗+抗PD-1疗效相关的风险致癌改变(例如，PIK3CA和TET2突变)。

结合这些免疫原性特征和癌原性改变，建立了食管癌基因组免疫肿瘤分类(EGIC)方案。化疗+抗PD-1在EGIC1(免疫原性特征有利和癌原性改变阴性)和EGIC2(免疫原性特征有利或癌原性改变阴性)亚组中获得了显著的生存改善，但在EGIC3亚组(免疫原性特征不利和癌原性改变阳性)中没有。因此，EGIC可能指导未来的个体化治疗策略，并为晚期ESCC患者化疗+抗PD-1治疗的机制生物标志物研究提供信息。

据介绍，虽然化疗+ PD-1阻断(化疗+抗PD-1)已成为晚期ESCC的标准一线治疗，但缺乏可靠的生物标志物。

附：英文原文

Title: An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma

Author: Yan-Xing Chen, Zi-Xian Wang, Ying Jin, Qi Zhao, Ze-Xian Liu, Zhi-Xiang Zuo, Huai-Qiang Ju, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li, Jifeng Feng, Lin Tian, Xiao-Jun Xia, Hui Feng, Sheng Yao, Feng-Hua Wang, Yu-Hong Li, Feng Wang, Rui-Hua Xu

Issue&Volume: 2023-04-13

Abstract: Although chemotherapy plus PD-1 blockade (chemo+anti-PD-1) has become the standardfirst-line therapy for advanced esophageal squamous cell carcinoma (ESCC), reliablebiomarkers for this regimen are lacking. Here we perform whole-exome sequencing ontumor samples from 486 patients of the JUPITER-06 study and develop a copy numberalteration-corrected tumor mutational burden that depicts immunogenicity more preciselyand predicts chemo+anti-PD-1 efficacy. We identify several other favorable immunogenicfeatures (e.g., HLA-I/II diversity) and risk oncogenic alterations (e.g., PIK3CA and TET2 mutation) associated with chemo+anti-PD-1 efficacy. An esophageal cancer genome-basedimmuno-oncology classification (EGIC) scheme incorporating these immunogenic featuresand oncogenic alterations is established. Chemo+anti-PD-1 achieves significant survivalimprovements in EGIC1 (immunogenic feature-favorable and oncogenic alteration-negative)and EGIC2 (either immunogenic feature-favorable or oncogenic alteration-negative)subgroups, but not the EGIC3 subgroup (immunogenic feature-unfavorable and oncogenicalteration-positive). Thus, EGIC may guide future individualized treatment strategiesand inform mechanistic biomarker research for chemo+anti-PD-1 treatment in patientswith advanced ESCC.

DOI: 10.1016/j.ccell.2023.03.016

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00089-2

Cancer Cell：《癌细胞》，创刊于2002年。隶属于细胞出版社，最新IF：38.585
官方网址：https://www.cell.com/cancer-cell/home
投稿链接：https://www.editorialmanager.com/cancer-cell/default.aspx